0.8395
price up icon7.13%   +0.0559
after-market  After Hours:  .8395 
loading
Virax Biolabs Group Ltd stock is currently priced at $0.8395, with a 24-hour trading volume of 22,156. It has seen a +7.13% increased in the last 24 hours and a +22.04% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $0.7912 pivot point. If it approaches the $0.8412 resistance level, significant changes may occur.
Previous Close:
$0.7836
Open:
$0.8
24h Volume:
22,156
Market Cap:
$1.98M
Revenue:
$79,300
Net Income/Loss:
$-6.92M
P/E Ratio:
-1.3154
EPS:
-0.6382
Net Cash Flow:
$-5.34M
1W Performance:
+4.94%
1M Performance:
+22.04%
6M Performance:
+217.27%
1Y Performance:
+129.31%
1D Range:
Value
$0.79
$0.8395
52W Range:
Value
$0.1299
$1.85

Virax Biolabs Group Ltd Stock (VRAX) Company Profile

Name
Name
Virax Biolabs Group Ltd
Name
Phone
44 20 7788 7414
Name
Address
30 Broadwick Street, London
Name
Employee
5
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
VRAX's Discussions on Twitter

Virax Biolabs Group Ltd Stock (VRAX) Financials Data

Virax Biolabs Group Ltd (VRAX) Revenue 2024

VRAX reported a revenue (TTM) of $79.30 thousand for the quarter ending September 30, 2023.
loading

Virax Biolabs Group Ltd (VRAX) Net Income 2024

VRAX net income (TTM) was -$6.92 million for the quarter ending September 30, 2023, a -705.15% decrease year-over-year.
loading

Virax Biolabs Group Ltd (VRAX) Cash Flow 2024

VRAX recorded a free cash flow (TTM) of -$5.34 million for the quarter ending September 30, 2023, a -1,088% decrease year-over-year.
loading

Virax Biolabs Group Ltd (VRAX) Earnings per Share 2024

VRAX earnings per share (TTM) was -$18.98 for the quarter ending September 30, 2023, a -2,410% decline year-over-year.
loading
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.
$77.56
price up icon 0.77%
$149.40
price down icon 1.20%
$29.98
price up icon 1.11%
$172.85
price up icon 1.06%
$365.81
price down icon 2.87%
$90.61
price down icon 2.55%
Cap:     |  Volume (24h):